Text resize: A A A

milestones

2000 | 2001 | 2002 | 2003 | 2005| 2006| 2007| 2008| 2009

With the acquisition of Roche’s API business at the Mexico site, Dr. Reddy’s will emerge as a leading player in Custom Pharmaceutical Services (CPS) business and position itself as a partner of choice for Innovator Companies across the globe with service offerings spanning the entire value chain of pharmaceutical services.

G. V. Prasad Vice-Chairman and CEO, Dr.Reddy's

Acquires ROCHE’s API Plant in Mexico

Dr. Reddy’s acquires Roche’s API business at the state-of-the-art manufacturing site in Cuernavaca, Mexico including all employees and business supply contracts for a total investment outlay of
USD 59 million including working capital.

This strategic acquisition provides an opportunity for the company’s CPS business to grow from its current base of USD10 million to USD100 million over the next 18 months. It provides a strong foundation to drive the next wave of growth in our CPS business.

This business involves the manufacture and sale of APIs including intermediates to Roche and other innovator companies. The product portfolio currently comprises about 18 products including mature APIs and a range of intermediates and steroids. This acquisition also adds unique steroids manufacturing capabilities to Dr. Reddy’s. The Cuernavaca site at Mexico is approved by U.S.FDA and other international regulatory agencies.

Click to read related memories

2005

Satish Reddy with Dr. Jan Van Koeveringe (Head of Pharma Global Technical Operations, Roche) at the handing over ceremony